RLMD — Relmada Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $93.24m
- $22.80m
- 24
- 22
- 35
- 16
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 9.22 | 117 | 212 | 148 | 96.3 |
Net Total Receivables | 0.247 | 0.079 | 0.086 | 0.512 | 0 |
Prepaid Expenses | |||||
Total Current Assets | 9.98 | 118 | 223 | 153 | 97.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.007 | 0.001 | 0 | — | — |
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 10.2 | 118 | 223 | 153 | 97.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.61 | 12.6 | 15.1 | 12.5 | 12.2 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 2.61 | 12.6 | 15.1 | 12.5 | 12.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 7.61 | 106 | 208 | 140 | 85.4 |
Total Liabilities & Shareholders' Equity | 10.2 | 118 | 223 | 153 | 97.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |